These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37042571)

  • 21. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
    Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
    Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of Soshiho-tang in atopic dermatitis patients with gastrointestinal disorders: A double-blinded, randomized, and placebo-controlled clinical trial.
    Lee JH; Jo EH; Jung JY; Kang SJ; Yang GJ; Shim YH; Park MC
    J Ethnopharmacol; 2021 Jun; 274():114006. PubMed ID: 33766759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
    Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
    Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients' and Caregivers' Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries.
    Capozza K; Funk M; Hering M; Lang J; Merhand S; Manion R; Orevillo K; Picozza M; Proctor A; Schwennesen T; Begolka WS; Tullos K; Talent C; Tu M; Vastrup AS; Schwartz A
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):264-273.e1. PubMed ID: 36332836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.
    Simpson EL; Bieber T; Eckert L; Wu R; Ardeleanu M; Graham NM; Pirozzi G; Mastey V
    J Am Acad Dermatol; 2016 Mar; 74(3):491-8. PubMed ID: 26777100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel topical agent containing superoxide dismutase 100 000 IU and 4% of plant extracts as a mono-therapy for atopic dermatitis.
    Sgouros D; Katoulis A; Rigopoulos D
    J Cosmet Dermatol; 2018 Dec; 17(6):1069-1072. PubMed ID: 29134748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis.
    Achten R; Van der Rijst L; Piena M; Lamers H; De Beer F; De Bruin-Weller M; De Graaf M
    Acta Derm Venereol; 2023 Mar; 103():adv00881. PubMed ID: 36883875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement properties of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire item banks in adults with atopic dermatitis.
    Silverberg JI; Lai JS; Vakharia PP; Patel K; Singam V; Chopra R; Sacotte R; Patel N; Rastogi S; Kantor R; Hsu DY; Cella D
    J Am Acad Dermatol; 2020 May; 82(5):1174-1180. PubMed ID: 31812620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of Pruritus in Relation to Self-assessed Severity of Atopic Dermatitis.
    Huet F; Faffa MS; Poizeau F; Merhand S; Misery L; Brenaut E
    Acta Derm Venereol; 2019 Mar; 99(3):279-283. PubMed ID: 30264161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults.
    Silverberg JI; Gelfand JM; Margolis DJ; Boguniewicz M; Fonacier L; Grayson MH; Chiesa Fuxench ZC; Simpson EL; Ong PY
    J Allergy Clin Immunol Pract; 2019; 7(8):2699-2706.e7. PubMed ID: 31228619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].
    Haufe E; Abraham S; Heratizadeh A; Harder I; Zink A; Weisshaar E; Kleinheinz A; von Kiedrowski R; Worm M; Bell M; Wollenberg A; Neubert K; Staubach-Renz P; Hilgers M; Bieber T; Fell I; Homey B; Effendy I; Mempel M; Schäkel K; Beissert S; Weidinger S; Werfel T; Schmitt J
    Hautarzt; 2018 Oct; 69(10):815-824. PubMed ID: 30191254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey.
    Augustin M; Nosbaum A; Werfel T; Grond S; Reed C; Lampropoulou A; Tietz N; Irvine AD; Riedl E
    J Dermatolog Treat; 2023 Dec; 34(1):2276047. PubMed ID: 37965779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency and influence of "not relevant" responses on the Dermatology Life Quality Index among adults with atopic dermatitis.
    Barbieri JS; Chiesa Fuxench ZC; Shin DB; Takeshita J
    Qual Life Res; 2021 Jun; 30(6):1705-1713. PubMed ID: 33538979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of atopic dermatitis severity with cognitive function in adults.
    Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY; Cella D
    J Am Acad Dermatol; 2020 Nov; 83(5):1349-1359. PubMed ID: 32428607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physician Perception of Disease Severity and Treatment Outcomes for Children and Adolescents with Atopic Dermatitis in Emerging Economies.
    Tang MBY; Fatani M; Wiggins S; Maspero J
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):999-1013. PubMed ID: 35349107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: A retrospective analysis of a cross-sectional questionnaire survey.
    Kamei K; Hirose T; Yoshii N; Tanaka A
    J Dermatol; 2021 Oct; 48(10):1491-1498. PubMed ID: 34231235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal course of cognitive impairment in patients with atopic dermatitis.
    Jackson-Cowan L; Silverberg JI
    Arch Dermatol Res; 2023 Aug; 315(6):1553-1560. PubMed ID: 36708375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.